Cardiovascular risk and combined oral contraceptives: Clinical decisions in settings of uncertainty

American Journal of Obstetrics and Gynecology

Volumn 208, Issue 1, 2013, Pages 39-41

  Beller, Jennifer P ^a   McCartney, Christopher R ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

cardiovascular risk; combined oral contraceptives; myocardial infarction; polycystic ovary syndrome

Indexed keywords

GESTAGEN; ORAL CONTRACEPTIVE AGENT;

ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL DECISION MAKING; DRUG CONTRAINDICATION; FEMALE FERTILITY; HUMAN; HYPERTENSION; INTRAUTERINE CONTRACEPTIVE DEVICE; ISCHEMIC HEART DISEASE; OVARY POLYCYSTIC DISEASE; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SEXUAL BEHAVIOR; SMOKING; WORLD HEALTH ORGANIZATION;

CARDIOVASCULAR DISEASES; CONTRACEPTIVES, ORAL, COMBINED; DECISION MAKING; FEMALE; HUMANS; PREGNANCY; RISK FACTORS; UNCERTAINTY;

EID: 84871607415     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2012.01.037     Document Type: Article

References (19)

1. D.B. Petitti Clinical practice Combination estrogen-progestin oral contraceptives N Engl J Med 349 2003 1443 1450
2. Y.S. Khader, J. Rice, L. John, O. Abueita Oral contraceptives use and the risk of myocardial infarction: a meta-analysis Contraception 68 2003 11 17
3. J.P. Baillargeon, D.K. McClish, P.A. Essah, J.E. Nestler Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis J Clin Endocrinol Metab 90 2005 3863 3870
4. Cardiovascular disease and steroid hormone contraception Report of a WHO Scientific Group World Health Organization technical report series 877 i-vii 1998 1 89
5. R.A. Wild, E. Carmina, E. Diamanti-Kandarakis Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society J Clin Endocrinol Metab 95 2010 2038 2049
6. P.C. de Groot, O.M. Dekkers, J.A. Romijn, S.W. Dieben, F.M. Helmerhorst PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis Hum Reprod Update 17 2011 495 500
7. Medical eligibility for contraceptive use 3rd ed. 2004 World Health Organization Geneva (Switzerland) http://whqlibdoc.who.int/publications/2004/ 9241562668.pdf Accessed April 30, 2010
8. American College of Obstetricians and Gynecologists ACOG practice bulletin no. 73: use of hormonal contraception in women with coexisting medical conditions Obstet Gynecol 107 2006 1453 1472
9. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
10. R.B. D'Agostino Sr, R.S. Vasan, M.J. Pencina General cardiovascular risk profile for use in primary care: the Framingham Heart Study Circulation 117 2008 743 753
11. E. Diamanti-Kandarakis Role of obesity and adiposity in polycystic ovary syndrome Int J Obes (Lond) 31 Suppl 2 2007 S8 S13
12. K.M. Hoeger Exercise therapy in polycystic ovary syndrome Semin Reprod Med 26 2008 93 100
13. L.J. Moran, G.D. Brinkworth, R.J. Norman Dietary therapy in polycystic ovary syndrome Semin Reprod Med 26 2008 85 92
14. K.A. Martin, R.J. Chang, D.A. Ehrmann Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society clinical practice guideline J Clin Endocrinol Metab 93 2008 1105 1120
15. D.A. Ehrmann Polycystic ovary syndrome N Engl J Med 352 2005 1223 1236
16. T. Tang, J.M. Lord, R.J. Norman, E. Yasmin, A.H. Balen Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility Cochrane Database Syst Rev 2010 CD003053
17. S. Palomba, A. Falbo, F. Zullo, F. Orio Jr Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review Endocr Rev 30 2009 1 50
18. R. Azziz, E. Carmina, D. Dewailly Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline J Clin Endocrinol Metab 91 2006 4237 4245
19. R.B. D'Agostino Sr, S. Grundy, L.M. Sullivan, P. Wilson CHD Risk Prediction Group Validation of the Framingham Coronary Heart Disease prediction scores - results of a multiple ethnic groups investigation JAMA 286 2001 180 187